Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#4481 Predicting peptide receptor radionuclide therapy (PRRT) response through the landscape of the immune microenvironment in neuroendocrine tumours

Introduction: Neuroendocrine tumours (NETs) often have poor prognosis upon metastasis. Peptide receptor radionuclide therapy (PRRT) is a novel treatment leveraging targeted cytotoxicity of radionuclides to efficiently address primary and metastatic tumours of NETs.

Conference:

Presenting Author: Yu J

Authors: Zeng Z, Lu M, Xie Q, Li J, Yang Z,

Keywords: peptide receptor radionuclide therapy, neuroendocrine tumour, tumour immune microenvironment, tumour response, therapeutic effect prediction,

#4428 Tumour-derived apolipoprotein E drives temozolomide chemoresistance by reprogramming lipid metabolism and activating the homologous recombination repair pathway in pancreatic neuroendocrine tumours

Introduction: Temozolomide (TMZ) is a first-class clinical drug for patients with pancreatic neuroendocrine tumours (pNETs). However, the therapeutic effects of TMZ are limited because of the chemoresistance of pNET cells.

Conference:

Presenting Author: Ji S

Authors: Lou X, Ji S, Xu X, Chen J, Yu X,

Keywords: Temozolomide, pancreatic neuroendocrine tumour, chemoresistance,

#3643 Effect of resection timing as part of multidisciplinary treatment for pancreatic NEN liver metastases

Introduction: Liver metastases are treated by resection if radical resection is possible as a part of multidisciplinary treatment along with pharmacotherapy and TACE.

Conference:

Presenting Author:

Authors: Masui T, Nagai K, Anazawa T, Kasai Y, Yogo A,

Keywords: liver metastasis, multidisciplinary treatment,

#3185 Targeted and photodynamic therapeutic effect of octreotide nano-micelles loaded with chlorin e6 on neuroendocrine tumors

Introduction: Nanotechnology combined with photodynamic treatment (PDT) has attracted extensive attention due to the targeted treatment of specific receptors and improve the efficacy. The treatment with PDT on neuroendocrine neoplasms is not reported yet.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Tang Q, Bai J, Yan L,

Keywords: neuroendocrine neoplasm, photodynamic treatment, nanotechnology, octreotide,

#2883 Comparison of Somatostatin Analogues in Metastatic Gastroenteropancreatic Neuroendocrine Tumors from a Bayesian Perspective: The GETNE-TRASGU Study

Introduction: Somatostatin analogues (SSA), octreotide LAR (Oct) and lanreotide autogel (Lan), significantly prolong progression-free survival (PFS) in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NET). However, comparative data are not available and randomized trials comparing both SSAs are unlikely to be conducted.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Carmona-Bayonas A, Jimenez-Fonseca P, Lamarca A, Barriuso J, Castaño A,

Keywords: Bayesian model, octreotide, lanreotide, progression-free survival, efficacy,